DE vs PFE: Which Is the Better Buy?
Side-by-side comparison of Deere & Company and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-06-20.
Deere & Company · Industrials
$589.24
-29.6% upside to fair value
Grade D
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
DE |
PFE |
| Current Price |
$589.24 |
$25.22 |
| Fair Value Estimate |
$414.61 |
$25.92 |
| Upside to Fair Value |
-29.6%
|
+2.8%
|
| Market Cap |
$159.1B |
$143.7B |
| Forward P/E |
33.3x
|
19.2x
|
| EV / EBITDA |
18.8x
|
12.3x
|
| Price / Sales |
3.4x
|
2.3x
|
| Price / FCF |
42.2x
|
15.2x
|
| Revenue Growth YoY |
+6.7%
|
+5.4%
|
| Gross Margin |
35.4%
|
69.3%
|
| Operating Margin |
18.4%
|
23.4%
|
| Return on Equity |
18.3%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
2.37%
|
6.6%
|
| Analyst Consensus |
Hold
|
Hold
|
Investment Thesis
Deere & Company is a leading global manufacturer of agricultural, construction, and forestry machinery with a durable competitive moat anchored by its number one market share in large agricultural equipment and a dense dealer network. The company benefits from embedded precision agriculture technology that widens its competitive gap, particularly in North America where it holds 40 to 60 percent m…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
DE |
PFE |
| Zone Low |
$310.96 |
$19.44 |
| Zone High |
$352.42 |
$22.03 |
| In Buy Zone? |
No
|
No
|